Substipharm
Private Company
Funding information not available
Overview
Substipharm is a fast-growing, privately-held French pharmaceutical group with a dual focus on niche generic drugs and vaccines. Its business model combines in-house pharmaceutical dossier development, targeted acquisitions, and international commercialization through both direct sales and partnerships. Recent strategic moves, including the acquisition of the IMOJEV® vaccine and expansion into biologics, underscore its ambition to become a significant player in providing accessible medicines in emerging and established markets globally.
Technology Platform
Expertise in pharmaceutical dossier development for generics and established medicines; commercial and partnership platform for vaccines; investment in drug delivery technology (Lauriad®).
Opportunities
Risk Factors
Competitive Landscape
In generics, competes with other mid-sized European generics firms and large global generics manufacturers in niche therapeutic areas. In vaccines, competes directly with major multinationals (Sanofi, GSK) and regional players in the Asia-Pacific market for JE and enterovirus vaccines. Its agility and focus on differentiated products are key competitive advantages.